Jasper Therapeutics, Inc. — Form 8-K Summary
Reporting date: February 25, 2022; filed February 28, 2022. The filing reports executive leadership and compensation changes, not quarterly or annual financial results.
Business Context and Reporting Period
Jasper Therapeutics is a Delaware biotechnology company headquartered in Redwood City, California, with common stock and redeemable warrants listed on Nasdaq under JSPR and JSPRW, respectively. The company identified itself as an emerging growth company.
Key Financial and Operating Metrics
- Revenue, net income, cash flow, margins, debt, and liquidity: The filing does not provide financial statements or a clear value for these metrics.
- Executive compensation: Incoming President and Chief Executive Officer Ronald Martell will receive an initial annualized salary of $675,000 and will be eligible for an annual performance bonus of up to 50% of base salary.
- Equity compensation: Subject to board or compensation committee approval, Mr. Martell will receive an option for 4.5% of the company’s outstanding voting common stock, measured at grant. The option will generally vest over four years.
Material Changes and Management Transition
- On February 25, 2022, the board appointed Ronald Martell as President and Chief Executive Officer and as a Class III director, effective upon commencement of employment, expected March 15, 2022.
- William Lis will become non-executive Chairperson of the Board when Mr. Martell begins employment. Mr. Lis had been President, CEO, and Executive Chairman.
- The filing describes Mr. Martell’s extensive biotechnology industry experience, including senior roles at MorphImmune, Nuvelution Pharma, Indapta Therapeutics, Orca Bio, Achieve Life Sciences, and commercial leadership experience at ImClone Systems and Genentech.
Outlook, Contingencies, and Unusual Items
- If Jasper closes an equity financing of at least $50 million after Mr. Martell’s employment begins, he will be eligible, subject to approval, for an additional option for 1.0% of outstanding voting common stock. This option would generally vest over four years.
- If Mr. Martell is terminated without “Cause” or resigns for “Good Reason,” he will be entitled to 18 months of base salary, subject to execution of a release in favor of the company.
- Employment is at will, and salary and bonus terms may be adjusted at the Compensation Committee’s discretion.
- The filing does not provide new clinical, commercial, financial, or company-wide business guidance.
- No reportable family relationships or related-party transactions involving Mr. Martell were disclosed.
Investor Verification Checklist
- Confirm the actual employment commencement date and completion of the CEO transition.
- Review Exhibit 10.1 for the complete employment, severance, option, and termination provisions.
- Verify whether the 4.5% option and any potential 1.0% financing-related option were approved and granted, and assess resulting dilution.
- Monitor whether the company completes an equity financing of at least $50 million, which would trigger eligibility for the additional option.
- Consult subsequent filings for updated cash, liquidity, financing, clinical development, and operating information, none of which is provided in this Form 8-K.